Growth Hormone Peptides ·
GHRP-2 may play a significant role in addressing hypothalamic dysfunction observed in long COVID patients. Recent studies suggest that endocrine dysfunction, particularly involving the hypothalamic-pituitary axis, is a concern in long COVID cases. This article examines the implications of GHRP-2 in this context, highlighting findings from a recent study that investigated hormonal responses in affected individuals.
What this study examined
The study published in the International Journal of Molecular Sciences focused on the hypothalamic-pituitary responses in patients suffering from long COVID. Conducted at a university hospital, the research involved a retrospective analysis of 1,251 patients diagnosed with long COVID between February 2021 and November 2025. Out of these, 207 patients exhibited low levels of adrenocorticotropic hormone (ACTH) or cortisol. A subset of 16 patients underwent anterior pituitary stimulation tests to assess their hormonal responses, particularly to corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH), and gonadotropin-releasing hormone (GnRH).
Why it matters for GHRP-2 research
The findings from this study underscore the potential involvement of GHRP-2 in addressing hormonal dysregulation in long COVID patients. GHRP-2, a growth hormone-releasing peptide, has shown promise in stimulating growth hormone (GH) release, which may be beneficial in patients exhibiting delayed hormonal responses. The study indicated that while peak hormonal responses were preserved, the timing of these responses was significantly delayed, suggesting a functional secondary hypothalamic dysfunction. This aligns with the potential therapeutic role of GHRP-2 in restoring hormonal balance.
Key findings
- Out of 1,251 long COVID patients, 207 had low random ACTH or cortisol levels.
- Only 16 patients underwent anterior pituitary stimulation tests, revealing delayed hormonal responses.
- Peak responses for ACTH, TSH, PRL, FSH, and LH were preserved but delayed beyond 60 minutes.
- Serum IGF-I levels were lowered, while GH response was preserved with GHRP-2 stimulation.
- Common symptoms among patients included fatigue, insomnia, and brain fog.
- Low-dose hydrocortisone and testosterone were initiated for some patients, indicating ongoing endocrine evaluation.
How GHRP-2 works (background)
GHRP-2 functions as a potent stimulant of growth hormone release from the anterior pituitary gland. It acts by binding to specific receptors on pituitary somatotrophs, leading to increased secretion of growth hormone. This mechanism is particularly relevant in conditions characterized by hormonal imbalances, such as those observed in long COVID. The peptide may enhance the overall endocrine response, potentially mitigating symptoms associated with hormonal deficiencies. Understanding the biological pathways influenced by GHRP-2 can aid researchers in developing targeted therapies for patients experiencing endocrine dysfunction.
Practical takeaways for researchers
Researchers exploring the implications of GHRP-2 should consider its potential role in managing hormonal dysregulation, especially in populations with conditions like long COVID. The findings from the recent study highlight the necessity of thorough endocrine evaluations before initiating hormone replacement therapies. Additionally, the preserved GH response to GHRP-2 suggests that further investigation into its therapeutic applications may be warranted. Researchers are encouraged to explore the mechanisms by which GHRP-2 can influence endocrine pathways and its potential benefits in clinical settings.
FAQ
What is GHRP-2?
GHRP-2 is a growth hormone-releasing peptide that stimulates the secretion of growth hormone from the pituitary gland, potentially aiding in hormonal balance.
How does GHRP-2 affect hormonal responses?
GHRP-2 enhances the release of growth hormone and may help restore normal hormonal responses in patients with endocrine dysfunction.
Are there any known side effects of GHRP-2?
While GHRP-2 is generally considered safe, potential side effects can include changes in appetite and water retention. Further studies are needed to fully understand its safety profile.
Source: PubMed · Int J Mol Sci · published 2026-01-14.